Promore Pharma AB engages in the development of therapeutic peptides for the bioactive wound care market. Its projects include PXL01 and LL-37. The PXL01 project will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical Phase III-studies in patients undergoing tendon repair surgery in the hand. The LL-37 project will used to prepare for a clinical Phase IIb study in patients with venous leg ulcers. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.